United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold the resulting common shares under a pre-arranged Rule 10b5-1 trading plan. She exercised 9,500 stock options at an exercise price of $146.03 per share and received an equal number of common shares.
On the same date, she sold 9,500 common shares in multiple open-market transactions at prices generally between about $570.51 and $578.68 per share, leaving 50,013 common shares held directly. Additional common shares are held indirectly through various family trusts and by her spouse, as disclosed in the footnotes.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sale transaction in company stock. He exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and, on the same date, sold 10,000 shares in multiple open-market trades at weighted average prices generally between about $568 and $579 per share. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, he directly holds 18,876 shares of Common Stock.
UNITED THERAPEUTICS Corp President and COO Michael Benkowitz reported gifting stock options rather than trading shares in the market. He made two bona fide gift transfers of stock options covering a total of 23,456 underlying shares of common stock, split into 11,728 options from direct holdings and 11,728 options from indirect holdings.
Each option has an exercise price of $217.50 per share and an expiration date of March 15, 2033. After the indirect gift, 99,720 stock options are shown as held indirectly in trusts beneficially owned by him, for which he has sole investment and voting power. Code G indicates these are non‑sale, bona fide gifts rather than open‑market sales.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 common shares in multiple open‑market trades at weighted average prices around $575–$584. These transactions were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025.
After the transactions, Rothblatt holds 40,513 common shares directly, additional shares indirectly through family trusts and a spouse, and 240,410 stock options expiring on March 17, 2027.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. On May 12, 2026, she exercised 9,500 stock options at $146.03 per share to acquire common stock, then sold 9,500 shares in multiple open-market trades around $570–$583 per share.
The filing states these moves were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the transactions, Rothblatt directly holds 40,513 shares of common stock and also has additional indirect holdings through family trusts and her spouse. The trading plan will continue until the earlier of the exercise of 1,734,410 stock options, which expire on March 17, 2027, or December 31, 2026.
UNITED THERAPEUTICS Corp director Nilda Mesa sold shares in an open‑market transaction. On this trade, Mesa sold 258 shares of common stock at a price of $581.935 per share. After the sale, Mesa directly owned 5,028 shares of UNITED THERAPEUTICS common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported exercising stock options for 9,500 shares of common stock at an exercise price of $146.03 per share on May 11, 2026, then selling 9,500 shares in multiple open‑market transactions.
The sales occurred at weighted average prices generally between about $568.89 and $580.45 per share, with individual trades reported around the high‑$560s to low‑$580s. According to a footnote, this exercise and sale sequence was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until up to 1,734,410 stock options expiring on March 17, 2027 are exercised or until December 31, 2026, whichever comes first.
Rothblatt also reports significant indirect holdings of UNITED THERAPEUTICS common stock through various family trusts and through a spouse, reflecting additional long‑term exposure separate from the directly held shares involved in these transactions.
United Therapeutics CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company common stock. On May 11, he exercised stock options for 10,000 shares at $135.42 per share and sold 10,000 shares in multiple open-market trades around the $570–$580 range under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 28,876 shares of common stock and 12,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. She exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in multiple open-market trades on May 8, 2026 at weighted average prices generally between the high $560s and low $570s per share. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. After these transactions, Rothblatt directly holds 40,513 shares of common stock and has additional indirect holdings through various family trusts and her spouse.